Author

D. Kazandjian

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

A. Bolomsky· 1 shared A. Derkach· 1 shared A. Dogan· 1 shared A. Mikulasova· 1 shared B. Haupl· 1 shared B. Maes· 1 shared B. Oben· 1 shared B. T. Diamond· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bolomsky

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

Y. Yang, T. Oellerich, P. Chen, A. Bolomsky, M. Ceribelli, B. Haupl, G. W. Wright, J. D. Phelan, D. W. Huang, J. W. Lord, C. K. Van Winkle, X. Yu, J. Wisnieski, J. Q. Wang, F. A. Tosto, , R. M. Young

This study identifies how oncogenic RAS activates mTORC1 in multiple myeloma by co-opting amino acid sensing pathways through a novel signaling complex.

bioRxiv · Nov 28, 2021Cancer Biology

Whole genome sequencing provides evidence of two biologically and clinically distinct entities of asymptomatic monoclonal gammopathies: progressive versus stable myeloma precursor condition

B. Oben, G. Froyen, K. H. Maclachlan, D. Leongamornlert, F. Abascal, B. Zheng-Lin, V. Yellapantula, A. Derkach, E. Geerdens, B. T. Diamond, I. Arijs, B. Maes, K. Vanhees, M. Hultcrantz, E. E. Manasanch, , F. Maura

The paper uses whole genome sequencing to identify two distinct myeloma precursor conditions, progressive and stable, based on genomic features.

bioRxiv · Nov 6, 2020 · PreprintCancer Biology